Physician profile
David Lauck
NPI 1700178597
$7,473.32
in general payments reported to CMS, 2019-2025
35 companies · $1,872 in 2025
The $1,872 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,846 · 2020: $843 · 2021: $255 · 2022: $570 · 2023: $731 · 2024: $1,357 · 2025: $1,872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,959.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,183.89 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,000.71 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $624.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $623.20 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $599.85 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $538.16 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $251.12 | 2019-2025 | |
| Antares Pharma, INC. | $233.93 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Merck Sharp & Dohme LLC | $226.68 | 2019-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.28 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $207.41 | 2019-2025 | Veozah |
| Abbott Laboratories | $206.48 | 2023-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $172.66 | 2019-2020 | |
| Eisai INC. | $157.61 | 2020-2025 | |
| Exact Sciences Corporation | $145.06 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lauck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.